



DTW

D0310 US PCT

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Paul D. Golian
Type or print name

Signature

February 6, 2007
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

CONFIRMATION NO: 2857

MARTHA LI

INTERNATIONAL APPLICATION NO:

PCT/US0424424

U.S. APPLICATION NO: 10/567,867

371 DATE : 07/29/2004

FOR: BIOMARKERS OF CYCLIN-

DEPENDENT KINASE MODULATION

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant believes this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-3880.

In accordance with 37 C.F.R. §1.56, Applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Pursuant to the OG Notice of August 5, 2003 for U.S. national applications filed after June 30, 2003, the requirement for submitting a copy of each cited U.S. patent and each cited U.S. patent application publication is waived and, accordingly, copies of the U.S. patent and U.S. patent publications are not submitted. Copies of foreign patent documents and non-patent literature are enclosed.

publications are not submitted. Copies of foreign patent documents and non-patent literature are enclosed.

Some of the listed references were cited in a search report in a corresponding PCT International application. A copy of the search report is also enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000



Paul D. Golian
Attorney for Applicant
Reg. No. 42,591
Phone: (609) 252-4091
Date: February 6, 2007

Substitute for form 1449/PTO

COMPLETE IF KNOWN

Application Number	10/567867
Filing Date	07/29/2004
First Named Inventor	MARTHA LI
Art Unit	
Examiner Name	
Attorney Docket Number	D0310 US - PCT

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

Sheet

of

3

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	5,569,588	10/29/1996	Ashby et al.	
	AB	6,040,321	03/21/2000	Kim et al.	
	AC	6,214,852	04/10/2001	Kim et al.	
	AD	6,262,096	07/17/2001	Kim et al.	
	AE	6,515,004	02/04/2003	Misra et al.	
	AF	6,521,759	02/18/2003	Kim et al.	
	AG	6,783,961	08/31/2004	Edwards et al.	

U.S. PATENT APPLICATION PUBLICATIONS DOCUMENTS

Examiner Initials	Cite No.	Document Number	Publication date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AH	US 2004/0253606 A1	12/16/2004	Aziz et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Check box if English language translation is attached
	AI	WO2001/66719 A1	09/13/2001	PCT	ABSTRACT ONLY, abs, SEQ ID NO:s 2071 and 2072	<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>
						<input type="checkbox"/>

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

PTO/SB/08B (8/03) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE															
Substitute for form 1449/PTO <div style="text-align: center;"> INFORMATION DISCLOSURE STATEMENT BY APPLICANT(S) <i>(use as many sheets as necessary)</i> </div>		<div style="text-align: center; border: 1px solid black; background-color: #f0f0f0; margin-bottom: 5px;">COMPLETE IF KNOWN</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr><td style="width: 50%;">Application Number</td><td>10/567867</td></tr> <tr><td>Filing Date</td><td>07/29/2004</td></tr> <tr><td>First Named Inventor</td><td>MARTHA LI</td></tr> <tr><td>Art Unit</td><td></td></tr> <tr><td>Examiner Name</td><td></td></tr> <tr><td>Attorney Docket Number</td><td>D0310 US PCT</td></tr> </table>		Application Number	10/567867	Filing Date	07/29/2004	First Named Inventor	MARTHA LI	Art Unit		Examiner Name		Attorney Docket Number	D0310 US PCT
Application Number	10/567867														
Filing Date	07/29/2004														
First Named Inventor	MARTHA LI														
Art Unit															
Examiner Name															
Attorney Docket Number	D0310 US PCT														
Sheet	2	of	3												

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	2AA	Akama, Y. et al., "Frequent amplification of the Cyclin E Gene in Human Gastric Carcinomas", Jpn. J. Cancer Res., Vol. 86, pp. 617-621 (1995)	
	2AB	Blanchard, A. et al., "Sequence to array: Probing the genome's secrets", Nature Biotechnology, Vol. 14, pp. 1649 (1996)	
	2AC	Catzavelos, C. et al., "Decreased levels of the cell-cycle inhibitor p27 ^{Kip1} protein: Prognostic implications in primary breast cancer", Nature Medicine, Vol. 3(2), pp. 227-230 (1997)	
	2AD	Courjal, F. et al., "Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of Cyclin D1 in breast and Cyclin E in ovarian tumors", Int. J. Cancer, Vol. 69, pp. 247-253 (1996)	
	2AE	Draetta, G. et al., "Activation of cdc2 Protein Kinase during Mitosis in Human Cells: Cell Cycle-Dependent Phosphorylation and Subunit Rearrangement", Cell, Vol. 54, pp. 17-26 (1988)	
	2AF	Dynlacht, B. et al., "Specific Regulation of E2F Family Members by Cyclin-Dependent Kinases", Molecular and Cellular Biology, Vol. 17(7), pp. 3867-3875 (1997)	
	2AG	Fredersdorf, S. et al., "High level expression of p27 ^{Kip1} and cyclin D1 in some human breast cancer cells: Inverse correlation between the expression of p27 ^{Kip1} and degree of malignancy in human breast and colorectal cancers", PNAS, Vol. 94, pp.6380-6385 (1997)	
	2AH	Gould, Kathleen, "Cyclin-dependent protein kinases", Protein Kinases, pp. 149-166 (1994)	
	2AI	Harper, J. Wade, "Cyclin Dependent Kinase Inhibitors, Cancer Surveys, Vol. 29, pp. 91-107 (1997)	
	2AJ	Keyomarsi, K. et al., "Cyclin E, a Potential Prognostic Marker for Breast Cancer", Cancer Research, Vol. 54, pp. 380-385 (1994)	
	2AK	King, R. et al., "How Proteolysis Drives the Cell Cycle", Science, Vol. 274, pp. 1652-1659 (1996)	
	2AL	Kitahara, K. et al., "Concurrent amplification of Cyclin E and CDK2 Genes", Int. J. Cancer, Vol. 62, pp. 25-28 (1995)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

Sheet 3 of 3

COMPLETE IF KNOWN

Application Number	10/567867
Filing Date	07/29/2004
First Named Inventor	MARTHA LI
Art Unit	
Examiner Name	
Attorney Docket Number	D0310 US PCT

NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article(when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Check box if English language Translation is attached
	3AA	Li, J. et al., "Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation", PNAS, Vol. 94, pp. 502-507 (1997)	
	3AB	Lockhart, D. et al., "Expression monitoring by hybridization to high-density oligonucleotide arrays", Nature Biotechnology, Vol. 14, pp. 1675-1680 (1996)	
	3AC	Morgan, David, "Principles of CDK regulation", Nature, Vol. 374, pp. 131-134 (1995)	
	3AD	Nigg, Erich, "Cellular substrates of p34 ^{cdc2} and its companion cyclin-dependent kinases", Trends in Cell Biology, Vol. 3, pp. 296-301 (1993)	
	3AE	Ookata, K. et al., "MAP4 Is the in Vivo Substrate for CDC2 Kinase in HeLa Cells: Identification of an M-Phase Specific and a Cell Cycle-Independent Phosphorylation Site in MAP4", Biochemistry, Vol. 36, pp. 15873-15883 (1997)	
	3AF	Pines, J. et al., "Isolation of a Human Cyclin cDNA: Evidence for Cyclin mRNA and Protein Regulation in the Cell Cycle and for Interaction with p34 ^{cdc2} ", Cell, Vol. 58, pp. 833-846 (1989)	
	3AG	Porter, P. et al., "Expression of cell-cycle regulators p27 ^{Kip1} and cyclin E, alone and in combination, correlate with survival in young breast cancer patients", Nature Medicine, Vol. 3(2), pp. 222-225 (1997)	
	3AH	Rickert, P. et al., "Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II", Oncogene, Vol. 12, pp. 2631-2640 (1996)	
	3AI	Schena, M. et al., "Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray", Science, Vol. 270, pp. 467-470 (1995)	
	3AJ	Tan, P. et al., "The Cell Cycle Inhibitor p27 Is an Independent Prognostic Marker in Small (T _{1a,b}) Invasive Breast Carcinomas", Cancer Research, Vol. 57, pp. 1259-1263 (1997)	
	3AK	Wang, A. et al., "Different expression patterns of cyclins A, D1 and E in human colorectal cancer", J. Cancer Res Clin Oncol, Vol. 122, pp. 122-126 (1996)	
	3AL	Van den Heuvel, S. et al., "Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control", Science, Vol. 262, pp. 2050-2054 (1993)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.